Exploration on Mechanism of Futu Shengjin Rehabilitation Formula in Regulating Immune Function During COVID-19 Convalescence Based on the Network Pharmacology
-
摘要:
目的 探讨扶土生金康复方治疗新型冠状病毒肺炎恢复期免疫抑制的作用机制。 方法 采用中医药网络药理学智能信息平台，检索扶土生金康复方的化学成分以及对应的靶点，通过GeneCards数据库获得免疫抑制相关靶点，将药物成分靶点与免疫抑制相关靶点对应，筛选交集靶点及相关功效成分。利用Cytoscape软件，构建“中药-成分-作用靶点-疾病”网络。通过STRING平台，进行PPI网络构建，找出核心靶点，再对交集靶点进行GO、KEGG富集分析。 结果 扶土生金康复方作用于免疫抑制的活性成分主要为槲皮素、木犀草素、山柰酚、柚皮素等，关键靶点为mTOR、TLR2、TNF、AKT1、MAPK3等，GO与KEGG富集分析提示通过T细胞活化、氧化应激等参与体内生物过程以及调控PI3K-Akt信号通路、EGFR酪氨酸激酶抑制剂耐药通路等方式调节免疫功能。 结论 阐述了扶土生金康复方治疗新型冠状病毒肺炎恢复期免疫抑制的作用机制，为未来研究提供了理论基础和研究方向。 -
关键词:
- 网络药理学 /
- 扶土生金康复方 /
- 新型冠状病毒肺炎恢复期 /
- 免疫抑制 /
- 作用机制
Abstract:OBJECTIVE To explore the mechanism of Futu Shengjin rehabilitation formula in the treatment of immunosuppression during COVID-19 convalescence. METHODS Using the TCM network pharmacology intelligent information platform, the chemical components and corresponding targets of Futu Shengjin rehabilitative formula were retrieved. Immunosuppression-related targets were obtained through GeneCards database. The drug component targets were corresponding to immunosuppression-related targets, and the intersection targets and efficacy components were screened. Cytoscape software was used to construct a "Chinese medicine-ingredient-target-disease" network. Through the String platform, PPI network was constructed to find out the core targets, and then GO and KEGG enrichment analysis was conducted on the intersection targets. RESULTS The active ingredients of Futu Shengjin rehabilitative formula in the immunosuppression, were mainly for quercetin, luteolin, kaempferol, naringenin, key targets for propagated were mTOR, TLR2, TNF, AKT1, MAPK3. GO and KEGG enrichment analysis indicated that immune function was regulated through the T cell activation, involvement in biological processes such as oxidative stress, and regulate PI3K-Akt signal pathway, EGFR tyrosine kinase inhibitor resistant methods. CONCLUSION This study elaborates the mechanism of Futu Shengjin rehabilitation prescription in the treatment of immunosuppression during COVID-19 convalescence, providing a theoretical basis and research direction for future research. -
[1] 李泉, 张浩, 邓斯予, 等. 新型冠状病毒肺炎恢复期病毒核酸检测复阳患者与阴性患者外周血淋巴细胞亚群的表达及形态学特征的比较研究[J]. 重庆医学, 2020, 49(19): 3151-3155. doi: 10.3969/j.issn.1671-8348.2020.19.002 [2] 史锁芳, 方祝元, 熊侃, 等. 扶土生金康复方治疗COVID-19恢复期肺脾不足证患者临床观察[J]. 南京中医药大学学报, 2020, 36(3): 281-285. https://www.cnki.com.cn/Article/CJFDTOTAL-NJZY202003002.htm [3] DING W, GU J, CAO L, et al. Traditional Chinese herbs as chemical resource library for drug discovery of anti-infective and anti-inflammatory[J]. J Ethnopharmacol, 2014, 155(1): 589-598. doi: 10.1016/j.jep.2014.05.066 [4] OUYANG YB, YIN JM, WANG WJ, et al. Downregulated gene expression spectrum and immune responses changed during the disease progression in patients with COVID-19[J]. Clin Infect Dis, 2020, 71(16): 2052-2060. doi: 10.1093/cid/ciaa462 [5] LI H, LIU L, ZHANG DY, et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses[J]. Lancet, 2020, 395(10235): 1517-1520. doi: 10.1016/S0140-6736(20)30920-X [6] 冯娟, 闫奎坡, 朱翠玲, 等. 基于网络药理学与分子对接的加减香砂六君子汤治疗新型冠状病毒肺炎恢复期肺脾气虚证的机制研究[J]. 药物评价研究, 2020, 43(9): 1673-1684. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ202009002.htm [7] XU Z, SHI L, WANG YJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X [8] MILENKOVIC M, ARSENOVIC-RANIN N, STOJIC-VUKANIC Z, et al. Quercetin ameliorates experimental autoimmune myocarditis in rats[J]. J Pharm Pharm Sci, 2010, 13(3): 311-319. doi: 10.18433/J3VS3S [9] CHIRUMBOLO S. The role of quercetin, flavonols and flavones in modulating inflammatory cell function[J]. Inflamm Allergy Drug Target, 2010, 9(4): 263-285. doi: 10.2174/187152810793358741 [10] 张桐茂, 刘炜, 孔德颖. 南葶苈子中的指标成分槲皮素-3-O-β-D-葡萄糖基-7-O-β-D-龙胆双糖苷对慢性阻塞性肺疾病大鼠肺部免疫功能调节机制研究[J]. 中草药, 2019, 50(4): 910-917. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYO201904018.htm [11] 周亮, 乔印玲, 王莉, 等. 木犀草素通过抑制PTEN PI3K-AKT信号通路以及对免疫功能的调节作用介导对肺癌模型大鼠的干预研究[J]. 天然产物研究与开发, 2017, 29(12): 2128-2133, 2140. https://www.cnki.com.cn/Article/CJFDTOTAL-TRCW201712024.htm [12] JUNG S, GAMEZ-DIAZ L, PROIETTI M, et al. "immune TOR-opathies", a novel disease entity in clinical immunology[J]. Front Immunol, 2018, 9: 966. doi: 10.3389/fimmu.2018.00966 [13] CHEN W, GHOBRIAL RM, LI XC, et al. Inhibition of RhoA and mTORC2/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages[J]. Immunobiology, 2018, 223(11): 634-647. doi: 10.1016/j.imbio.2018.07.009 [14] 周秀, 张慧, 钟小宁. 雷帕霉素及哺乳动物雷帕霉素靶蛋白(mTOR)在免疫调节中的作用研究进展[J]. 细胞与分子免疫学杂志, 2018, 34(10): 954-958. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM201810018.htm [15] 王孝勤, 张野, 白雪帆, 等. 乙型肝炎肝硬化患者外周血Toll样受体2和4及CD4+CD25+调节性T细胞的变化[J]. 中华微生物学和免疫学杂志, 2009, 29(5): 411-415. doi: 10.3760/cma.j.issn.0254-5101.2009.05.007 [16] JIN MS, LEE JO. Structures of the toll-like receptor family and its ligand complexes[J]. Immunity, 2008, 29(2): 182-191. doi: 10.1016/j.immuni.2008.07.007 [17] FELDMANN M, STEINMAN L. Design of effective immunotherapy for human autoimmunity[J]. Nature, 2005, 435(7042): 612-619. doi: 10.1038/nature03727 [18] BRAUMULLER H, WIEDER T, BRENNER E, et al. T-helper-1-cell cytokines drive cancer into senescence[J]. Nature, 2013, 494(7437): 361-365. doi: 10.1038/nature11824 [19] CROFT M. The role of TNF superfamily members in T-cell function and diseases[J]. Nat Rev Immunol, 2009, 9(4): 271-285. doi: 10.1038/nri2526 [20] AZIZ A, FARID S, QIN KR, et al. PIM kinases and their relevance to the PI3K/AKT/mTOR pathway in the regulation of ovarian cancer[J]. Biomolecules, 2018, 8(1): 7. doi: 10.3390/biom8010007 [21] LAWRENCE J, NHO R. The role of the mammalian target of rapamycin (mTOR) in pulmonary fibrosis[J]. Int J Mol Sci, 2018, 19(3): 778. doi: 10.3390/ijms19030778 [22] ZHOU KL, LIU L, SHI SF. Qu Feng Xuan Bi Formula attenuates anaphylactic rhinitis-asthma symptoms via reducing EOS count and regulating T cell function in rat ARA models[J]. J Ethnopharmacol, 2014, 152(3): 568-574. doi: 10.1016/j.jep.2014.02.006 [23] 周奎龙, 史锁芳, 王志恒, 等. 祛风宣痹方对实验性哮喘豚鼠气道炎症和Th1/Th2细胞因子的影响[J]. 中华中医药学刊, 2015, 33(8): 1991-1993, 2080. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201508067.htm -
下载:
点击查看大图
图(6)
计量
- 文章访问数: 410
- HTML全文浏览量: 94
- PDF下载量: 251
- 被引次数: 0
